UCB Inc. recently commissioned Milliman to estimate the average annual cost for indicated drug treatments in the commercial health insurance market for patients with generalized myasthenia gravis (gMG). Myasthenia gravis (MG) is an autoimmune disorder impacting the neuromuscular system, resulting in muscle weakness and fatigue. Six drugs on the market are indicated for gMG, a subset of MG that affects multiple muscle groups. Two UCB drugs indicated for gMG were approved in 2023. We break down the market and results for commercially insured patients with an MG diagnosis as follows: 

• Drugs approved to treat gMG 
• Costs by site of care
• Drug administration costs

This report was commissioned by UCB.